Bill Text: TX SB1646 | 2019-2020 | 86th Legislature | Introduced
Bill Title: Relating to the controlled substances listed in Penalty Groups 1, 2, and 2-A under the Texas Controlled Substances Act.
Spectrum: Partisan Bill (Democrat 1-0)
Status: (Introduced - Dead) 2019-03-14 - Referred to Criminal Justice [SB1646 Detail]
Download: Texas-2019-SB1646-Introduced.html
86R12665 JSC-F | ||
By: Miles | S.B. No. 1646 |
|
||
|
||
relating to the controlled substances listed in Penalty Groups 1, | ||
2, and 2-A under the Texas Controlled Substances Act. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Section 481.102, Health and Safety Code, is | ||
amended to read as follows: | ||
Sec. 481.102. PENALTY GROUP 1. Penalty Group 1 consists | ||
of: | ||
(1) the following opiates, including their isomers, | ||
esters, ethers, salts, and salts of isomers, esters, and ethers, | ||
unless specifically excepted, if the existence of these isomers, | ||
esters, ethers, and salts is possible within the specific chemical | ||
designation: | ||
Alfentanil; | ||
Allylprodine; | ||
Alphacetylmethadol; | ||
Benzethidine; | ||
Betaprodine; | ||
Clonitazene; | ||
Diampromide; | ||
Diethylthiambutene; | ||
Difenoxin not listed in Penalty Group 3 or 4; | ||
Dimenoxadol; | ||
Dimethylthiambutene; | ||
Dioxaphetyl butyrate; | ||
Dipipanone; | ||
Ethylmethylthiambutene; | ||
Etonitazene; | ||
Etoxeridine; | ||
Furethidine; | ||
Hydroxypethidine; | ||
Ketobemidone; | ||
Levophenacylmorphan; | ||
Meprodine; | ||
Methadol; | ||
Moramide; | ||
Morpheridine; | ||
Noracymethadol; | ||
Norlevorphanol; | ||
Normethadone; | ||
Norpipanone; | ||
Phenadoxone; | ||
Phenampromide; | ||
Phenomorphan; | ||
Phenoperidine; | ||
Piritramide; | ||
Proheptazine; | ||
Properidine; | ||
Propiram; | ||
Sufentanil; | ||
Tilidine; and | ||
Trimeperidine; | ||
(2) the following opium derivatives, their salts, | ||
isomers, and salts of isomers, unless specifically excepted, if the | ||
existence of these salts, isomers, and salts of isomers is possible | ||
within the specific chemical designation: | ||
Acetorphine; | ||
Acetyldihydrocodeine; | ||
Benzylmorphine; | ||
Codeine methylbromide; | ||
Codeine-N-Oxide; | ||
Cyprenorphine; | ||
Desomorphine; | ||
Dihydromorphine; | ||
Drotebanol; | ||
Etorphine, except hydrochloride salt; | ||
Heroin; | ||
Hydromorphinol; | ||
Methyldesorphine; | ||
Methyldihydromorphine; | ||
Monoacetylmorphine; | ||
Morphine methylbromide; | ||
Morphine methylsulfonate; | ||
Morphine-N-Oxide; | ||
Myrophine; | ||
Nicocodeine; | ||
Nicomorphine; | ||
Normorphine; | ||
Pholcodine; and | ||
Thebacon; | ||
(3) the following substances, however produced, | ||
except those narcotic drugs listed in another group: | ||
(A) Opium and opiate not listed in Penalty Group | ||
3 or 4, and a salt, compound, derivative, or preparation of opium or | ||
opiate, other than thebaine derived butorphanol, nalmefene and its | ||
salts, naloxone and its salts, and naltrexone and its salts, but | ||
including: | ||
Codeine not listed in Penalty Group 3 or 4; | ||
Dihydroetorphine; | ||
Ethylmorphine not listed in Penalty Group 3 | ||
or 4; | ||
Granulated opium; | ||
Hydrocodone not listed in Penalty Group 3; | ||
Hydromorphone; | ||
Metopon; | ||
Morphine not listed in Penalty Group 3; | ||
Opium extracts; | ||
Opium fluid extracts; | ||
Oripavine; | ||
Oxycodone; | ||
Oxymorphone; | ||
Powdered opium; | ||
Raw opium; | ||
Thebaine; and | ||
Tincture of opium; | ||
(B) a salt, compound, isomer, derivative, or | ||
preparation of a substance that is chemically equivalent or | ||
identical to a substance described by Paragraph (A), other than the | ||
isoquinoline alkaloids of opium; | ||
(C) Opium poppy and poppy straw; | ||
(D) Cocaine, including: | ||
(i) its salts, its optical, position, and | ||
geometric isomers, and the salts of those isomers; | ||
(ii) coca leaves and a salt, compound, | ||
derivative, or preparation of coca leaves; and | ||
(iii) a salt, compound, derivative, or | ||
preparation of a salt, compound, or derivative that is chemically | ||
equivalent or identical to a substance described by Subparagraph | ||
(i) or (ii), other than decocainized coca leaves or extractions of | ||
coca leaves that do not contain cocaine or ecgonine; and | ||
(E) concentrate of poppy straw, meaning the crude | ||
extract of poppy straw in liquid, solid, or powder form that | ||
contains the phenanthrine alkaloids of the opium poppy; | ||
(4) the following opiates and opioids, including their | ||
isomers, esters, ethers, salts, and salts of isomers, if the | ||
existence of these isomers, esters, ethers, and salts is possible | ||
within the specific chemical designation: | ||
(A) [ |
||
|
||
[ |
||
|
||
Alphaprodine; | ||
Anileridine; | ||
[ |
||
|
||
[ |
||
Bezitramide; | ||
[ |
||
Dihydrocodeine not listed in Penalty Group 3 or 4; | ||
Diphenoxylate not listed in Penalty Group 3 or 4; | ||
Fentanyl [ |
||
|
||
Isomethadone; | ||
Levomethorphan; | ||
Levorphanol; | ||
Metazocine; | ||
Methadone; | ||
Methadone-Intermediate, 4-cyano-2-dimethylamino- | ||
4, 4-diphenyl butane; | ||
[ |
||
|
||
[ |
||
|
||
Moramide-Intermediate, 2-methyl-3-morpholino-1, | ||
1-diphenyl-propane-carboxylic acid; | ||
Para-fluorofentanyl(N-(4-fluorophenyl)-N-1-(2- | ||
phenylethyl)-4-piperidinylpropanamide); | ||
PEPAP (1-(2-phenethyl)-4-phenyl-4- | ||
acetoxypiperidine); | ||
Pethidine (Meperidine); | ||
Pethidine-Intermediate-A, 4-cyano-1-methyl-4- | ||
phenylpiperidine; | ||
Pethidine-Intermediate-B, ethyl-4- | ||
phenylpiperidine-4 carboxylate; | ||
Pethidine-Intermediate-C, 1-methyl-4- | ||
phenylpiperidine-4-carboxylic acid; | ||
Phenazocine; | ||
Piminodine; | ||
Racemethorphan; and | ||
Racemorphan[ |
||
[ |
||
[ |
||
|
||
(B) a substance related to fentanyl, unless | ||
specifically excepted or controlled in another Penalty Group, | ||
including any substance that is structurally related to fentanyl by | ||
one or more of the following modifications: | ||
(i) substitution on or replacement of the | ||
phenethyl group, such as: | ||
Alpha methyl fentanyl; | ||
Benzyl fentanyl; and | ||
Thionyl fentanyl (HCl); | ||
(ii) substitution on the piperidine ring, | ||
such as: | ||
Carfentanil; | ||
3-Fluorofentanyl (HCl); and | ||
4-Phenyl fentanyl (HCl); | ||
(iii) substitution on the aniline ring, | ||
such as: | ||
para-Fluorofentanyl; | ||
meta-Fluorofentanyl; and | ||
ortho-Fluorofentanyl; and | ||
(iv) substitution or replacement of the | ||
N-propionyl group, such as: | ||
Acetyl fentanyl (HCL); | ||
Benzodioxole fentanyl; and | ||
Furanyl fentanyl (HCl); | ||
(5) Flunitrazepam (trade or other name: Rohypnol); | ||
(6) Methamphetamine, including its salts, optical | ||
isomers, and salts of optical isomers; | ||
(7) Phenylacetone and methylamine, if possessed | ||
together with intent to manufacture methamphetamine; | ||
(8) Phencyclidine, including its salts; | ||
(9) Gamma hydroxybutyric acid (some trade or other | ||
names: gamma hydroxybutyrate, GHB), including its salts; | ||
(10) Ketamine; | ||
(11) Phenazepam; | ||
(12) U-47700; | ||
(13) AH-7921; | ||
(14) ADB-FUBINACA; | ||
(15) AMB-FUBINACA; and | ||
(16) MDMB-CHMICA. | ||
SECTION 2. Section 481.103(a), Health and Safety Code, is | ||
amended to read as follows: | ||
(a) Penalty Group 2 consists of: | ||
(1) any quantity of the following hallucinogenic | ||
substances, their salts, isomers, and salts of isomers, unless | ||
specifically excepted, if the existence of these salts, isomers, | ||
and salts of isomers is possible within the specific chemical | ||
designation: | ||
5-(2-aminopropyl)benzofuran (5-APB); | ||
6-(2-aminopropyl)benzofuran (6-APB); | ||
5-(2-aminopropyl)-2,3-dihydrobenzofuran | ||
(5-APDB); | ||
6-(2-aminopropyl)-2,3-dihydrobenzofuran | ||
(6-APDB); | ||
5-(2-aminopropyl)indole (5-IT,5-API); | ||
6-(2-aminopropyl)indole (6-IT,6-API); | ||
1-(benzofuran-5-yl)-N-methylpropan-2-amine | ||
(5-MAPB); | ||
1-(benzofuran-6-yl)-N-methylpropan-2-amine | ||
(6-MAPB); | ||
Benzothiophenylcyclohexylpiperidine (BTCP); | ||
8-bromo-alpha-methyl-benzo[1,2-b:4,5-b']difuran- | ||
4-ethanamine (trade or other name: Bromo-DragonFLY); | ||
Desoxypipradrol (2-benzhydrylpiperidine); | ||
2, 5-dimethoxyamphetamine (some trade or other | ||
names: 2, 5-dimethoxy-alpha-methylphenethylamine; 2, 5-DMA); | ||
Diphenylprolinol (diphenyl(pyrrolidin-2-yl) | ||
methanol, D2PM); | ||
Dronabinol (synthetic) in sesame oil and | ||
encapsulated in a soft gelatin capsule in a U.S. Food and Drug | ||
Administration approved drug product (some trade or other names for | ||
Dronabinol: (a6aR-trans)-6a,7,8,10a-tetrahydro- 6,6, 9- | ||
trimethyl-3-pentyl-6H- dibenzo [b,d]pyran-1-ol or (-)-delta-9- | ||
(trans)- tetrahydrocannabinol); | ||
Ethylamine Analog of Phencyclidine (some trade or | ||
other names: N-ethyl-1-phenylcyclohexylamine, (1- | ||
phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, | ||
cyclohexamine, PCE); | ||
2-ethylamino-2-(3-methoxyphenyl)cyclohexanone | ||
(trade or other name: methoxetamine); | ||
Ibogaine (some trade or other names: 7-Ethyl-6, | ||
6, beta 7, 8, 9, 10, 12, 13-octahydro-2-methoxy-6, 9-methano-5H- | ||
pyrido [1', 2':1, 2] azepino [5, 4-b] indole; tabernanthe iboga.); | ||
5-iodo-2-aminoindane (5-IAI); | ||
Mescaline; | ||
5-methoxy-3, 4-methylenedioxy amphetamine; | ||
4-methoxyamphetamine (some trade or other | ||
names: 4-methoxy-alpha-methylphenethylamine; | ||
paramethoxyamphetamine; PMA); | ||
4-methoxymethamphetamine (PMMA); | ||
2-(2-methoxyphenyl)-2-(methylamino)cyclohexanone | ||
(some trade and other names: 2-MeO-ketamine; methoxyketamine); | ||
1-methyl- 4-phenyl-4-propionoxypiperidine (MPPP, | ||
PPMP); | ||
4-methyl-2, 5-dimethoxyamphetamine (some trade | ||
and other names: 4-methyl-2, 5-dimethoxy-alpha- | ||
methylphenethylamine; "DOM"; "STP"); | ||
3,4-methylenedioxy methamphetamine (MDMA, MDM); | ||
3,4-methylenedioxy amphetamine; | ||
3,4-methylenedioxy N-ethylamphetamine (Also | ||
known as N-ethyl MDA); | ||
5,6-methylenedioxy-2-aminoindane (MDAI); | ||
Nabilone (Another name for nabilone: (+)-trans- | ||
3-(1,1-dimethylheptyl)- 6,6a, 7,8,10,10a-hexahydro-1-hydroxy- 6, | ||
6-dimethyl-9H-dibenzo[b,d] pyran-9-one; | ||
N-benzylpiperazine (some trade or other | ||
names: BZP; 1-benzylpiperazine); | ||
N-ethyl-3-piperidyl benzilate; | ||
N-hydroxy-3,4-methylenedioxyamphetamine (Also | ||
known as N-hydroxy MDA); | ||
4-methylaminorex; | ||
N-methyl-3-piperidyl benzilate; | ||
Parahexyl (some trade or other names: 3-Hexyl-1- | ||
hydroxy-7, 8, 9, 10-tetrahydro-6, 6, 9-trimethyl-6H-dibenzo [b, d] | ||
pyran; Synhexyl); | ||
1-Phenylcyclohexylamine; | ||
1-Piperidinocyclohexanecarbonitrile (PCC); | ||
Pyrrolidine Analog of Phencyclidine (some trade | ||
or other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy, PHP); | ||
Tetrahydrocannabinols, other than marihuana, and | ||
synthetic equivalents of the substances contained in the plant, or | ||
in the resinous extractives of Cannabis, or synthetic substances, | ||
derivatives, and their isomers with similar chemical structure, | ||
[ |
||
delta-9-tetrahydrocannabinolic acid (some | ||
trade name or other name: THCA-A and THCA-B); | ||
delta-9-tetrahydrocannabinol, and its | ||
optical isomers; | ||
delta-1 cis or trans tetrahydrocannabinol, | ||
and their optical isomers; | ||
delta-6 cis or trans tetrahydrocannabinol, | ||
and their optical isomers; | ||
delta-3, 4 cis or trans | ||
tetrahydrocannabinol, and its optical isomers; or | ||
compounds of these structures, regardless of | ||
numerical designation of atomic positions, since nomenclature of | ||
these substances is not internationally standardized; | ||
Thiophene Analog of Phencyclidine (some trade or | ||
other names: 1-[1-(2-thienyl) cyclohexyl] piperidine; 2-Thienyl | ||
Analog of Phencyclidine; TPCP, TCP); | ||
1-pyrrolidine (some trade or other name: TCPy); | ||
1-(3-trifluoromethylphenyl)piperazine (trade or | ||
other name: TFMPP); and | ||
3,4,5-trimethoxy amphetamine; | ||
(2) Phenylacetone (some trade or other | ||
names: Phenyl-2-propanone; P2P, Benzymethyl ketone, methyl benzyl | ||
ketone); | ||
(3) unless specifically excepted or unless listed in | ||
another Penalty Group, a material, compound, mixture, or | ||
preparation that contains any quantity of the following substances | ||
having a potential for abuse associated with a depressant or | ||
stimulant effect on the central nervous system: | ||
Aminorex (some trade or other | ||
names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; 4,5-dihydro-5- | ||
phenyl-2-oxazolamine); | ||
Amphetamine, its salts, optical isomers, and | ||
salts of optical isomers; | ||
Cathinone (some trade or other names: 2-amino-1- | ||
phenyl-1-propanone, alpha-aminopropiophenone, 2- | ||
aminopropiophenone); | ||
Etaqualone and its salts; | ||
Etorphine Hydrochloride; | ||
Fenethylline and its salts; | ||
Lisdexamfetamine, including its salts, isomers, | ||
and salts of isomers; | ||
Mecloqualone and its salts; | ||
Methaqualone and its salts; | ||
Methcathinone (some trade or other names: 2- | ||
methylamino-propiophenone; alpha-(methylamino)propriophenone; | ||
2-(methylamino)-1-phenylpropan-1-one; alpha-N- | ||
methylaminopropriophenone; monomethylpropion; ephedrone, N- | ||
methylcathinone; methylcathinone; AL-464; AL-422; AL-463; and UR | ||
1431); | ||
N-Ethylamphetamine, its salts, optical isomers, | ||
and salts of optical isomers; and | ||
N,N-dimethylamphetamine (some trade or other | ||
names: N,N,alpha-trimethylbenzeneethanamine; | ||
N,N,alpha-trimethylphenethylamine), its salts, optical isomers, | ||
and salts of optical isomers; | ||
(4) any compound structurally derived from | ||
2-aminopropanal by substitution at the 1-position with any | ||
monocyclic or fused-polycyclic ring system, including: | ||
(A) compounds further modified by: | ||
(i) substitution in the ring system to any | ||
extent (including alkyl, alkoxy, alkylenedioxy, haloalkyl, or | ||
halide substituents), whether or not further substituted in the | ||
ring system by other substituents; | ||
(ii) substitution at the 3-position with an | ||
alkyl substituent; or | ||
(iii) substitution at the 2-amino nitrogen | ||
atom with alkyl, benzyl, dialkyl, or methoxybenzyl groups, or | ||
inclusion of the 2-amino nitrogen atom in a cyclic structure; and | ||
(B) by example, compounds such as: | ||
4-Methylmethcathinone (Also known as | ||
Mephedrone); | ||
3,4-Dimethylmethcathinone (Also known as | ||
3,4-DMMC); | ||
3-Fluoromethcathinone (Also known as 3-FMC); | ||
4-Fluoromethcathinone (Also known as | ||
Flephedrone); | ||
3,4-Methylenedioxy-N-methylcathinone (Also | ||
known as Methylone); | ||
3,4-Methylenedioxypyrovalerone (Also known | ||
as MDPV); | ||
alpha-Pyrrolidinopentiophenone (Also known | ||
as alpha-PVP); | ||
Naphthylpyrovalerone (Also known as | ||
Naphyrone); | ||
alpha-Methylamino-valerophenone (Also known | ||
as Pentedrone); | ||
beta-Keto-N-methylbenzodioxolylpropylamine | ||
(Also known as Butylone); | ||
beta-Keto-N-methylbenzodioxolylpentanamine | ||
(Also known as Pentylone); | ||
beta-Keto-Ethylbenzodioxolylbutanamine | ||
(Also known as Eutylone); and | ||
3,4-methylenedioxy-N-ethylcathinone (Also | ||
known as Ethylone); | ||
(5) any compound structurally derived from tryptamine | ||
(3-(2-aminoethyl)indole) or a ring-hydroxy tryptamine: | ||
(A) by modification in any of the following ways: | ||
(i) by substitution at the amine nitrogen | ||
atom of the sidechain to any extent with alkyl or alkenyl groups or | ||
by inclusion of the amine nitrogen atom of the side chain (and no | ||
other atoms of the side chain) in a cyclic structure; | ||
(ii) by substitution at the carbon atom | ||
adjacent to the nitrogen atom of the side chain (alpha-position) | ||
with an alkyl or alkenyl group; | ||
(iii) by substitution in the 6-membered | ||
ring to any extent with alkyl, alkoxy, haloalkyl, thioaklyl, | ||
alkylenedioxy, or halide substituents; or | ||
(iv) by substitution at the 2-position of | ||
the tryptamine ring system with an alkyl substituent; and | ||
(B) including: | ||
(i) ethers and esters of the controlled | ||
substances listed in this subdivision; and | ||
(ii) by example, compounds such as: | ||
alpha-ethyltryptamine; | ||
alpha-methyltryptamine; | ||
Bufotenine (some trade and other names: | ||
3-(beta-Dimethylaminoethyl)-5-hydroxyindole; | ||
3-(2-dimethylaminoethyl)- 5- indolol; N, N-dimethylserotonin; | ||
5-hydroxy-N, N- dimethyltryptamine; mappine); | ||
Diethyltryptamine (some trade and | ||
other names: N, N-Diethyltryptamine, DET); | ||
Dimethyltryptamine (trade or other | ||
name: DMT); | ||
5-methoxy-N, N-diisopropyltryptamine | ||
(5-MeO-DiPT); | ||
O-Acetylpsilocin (Trade or other name: | ||
4-Aco-DMT); | ||
Psilocin; and | ||
Psilocybin; | ||
(6) 2,5-Dimethoxyphenethylamine and any compound | ||
structurally derived from 2,5-Dimethoxyphenethylamine by | ||
substitution at the 4-position of the phenyl ring to any extent | ||
(including alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide | ||
substituents), including, by example, compounds such as: | ||
4-Bromo-2,5-dimethoxyphenethylamine (trade or | ||
other name: 2C-B); | ||
4-Chloro-2,5-dimethoxyphenethylamine (trade or | ||
other name: 2C-C); | ||
2,5-Dimethoxy-4-methylphenethylamine (trade or | ||
other name: 2C-D); | ||
4-Ethyl-2,5-dimethoxyphenethylamine (trade or | ||
other name: 2C-E); | ||
4-Iodo-2,5-dimethoxyphenethylamine (trade or | ||
other name: 2C-I); | ||
2,5-Dimethoxy-4-nitrophenethylamine (trade or | ||
other name: 2C-N); | ||
2,5-Dimethoxy-4-(n)-propylphenethylamine (trade | ||
or other name: 2C-P); | ||
4-Ethylthio-2,5-dimethoxyphenethylamine (trade | ||
or other name: 2C-T-2); | ||
4-Isopropylthio-2,5-dimethoxyphenethylamine | ||
(trade or other name: 2C-T-4); and | ||
2,5-Dimethoxy-4-(n)-propylthiophenethylamine | ||
(trade or other name: 2C-T-7); and | ||
(7) 2,5-Dimethoxyamphetamine and any compound | ||
structurally derived from 2,5-Dimethoxyamphetamine by substitution | ||
at the 4-position of the phenyl ring to any extent (including alkyl, | ||
alkoxy, alkylenedioxy, haloalkyl, or halide substituents), | ||
including, by example, compounds such as: | ||
4-Ethylthio-2,5-dimethoxyamphetamine (trade or | ||
other name: Aleph-2); | ||
4-Isopropylthio-2,5-dimethoxyamphetamine (trade | ||
or other name: Aleph-4); | ||
4-Bromo-2,5-dimethoxyamphetamine (trade or other | ||
name: DOB); | ||
4-Chloro-2,5-dimethoxyamphetamine (trade or | ||
other name: DOC); | ||
2,5-Dimethoxy-4-ethylamphetamine (trade or other | ||
name: DOET); | ||
4-Iodo-2,5-dimethoxyamphetamine (trade or other | ||
name: DOI); | ||
2,5-Dimethoxy-4-methylamphetamine (trade or | ||
other name: DOM); | ||
2,5-Dimethoxy-4-nitroamphetamine (trade or other | ||
name: DON); | ||
4-Isopropyl-2,5-dimethoxyamphetamine (trade or | ||
other name: DOIP); and | ||
2,5-Dimethoxy-4-(n)-propylamphetamine (trade or | ||
other name: DOPR). | ||
SECTION 3. Section 481.1031, Health and Safety Code, is | ||
amended to read as follows: | ||
Sec. 481.1031. PENALTY GROUP 2-A. (a) In this section: | ||
(1) "Core component" is one of the following: | ||
azaindole, beta carboline, benzimidazole, benzothiazole, | ||
carbazole, gamma carboline, imidazole, indane, indazole, indene, | ||
indole, naphthalene, pyrazole, pyrazolopyridine, pyridine, or | ||
pyrrole. | ||
(2) "Group A component" is one of the following: | ||
adamantane, benzylpiperazine, benzyl, cumene [ |
||
cycloalkylmethyl, cyclopropylmethyl, isoquinoline, | ||
methylpiperazine, naphthalene, pyrrolidine, phenyl, quinoline, | ||
tetrahydronaphthalene, tetramethylcyclopropane, amino oxobutane, | ||
amino methyl ovobutane, amino dimethyl oxobutane, amino phenyl | ||
oxopropane, amino oxopentane, ethoxy oxobutane, ethoxy methyl | ||
oxobutane, ethoxy dimethyl oxobutane, ethoxy phenyl oxopropane, | ||
ethoxy oxopentane, methoxy oxobutane, methoxy methyl oxobutane | ||
[ |
||
phenyl oxopropane, methoxy oxopentane, or any substituted [ |
||
amino acid. | ||
(3) "Link component" is one of the following | ||
functional groups: carboxamide, carboxylate, hydrazide, | ||
methanone (ketone), ethanone, methanediyl (methylene bridge), or | ||
methine. | ||
(b) Penalty Group 2-A consists of any material, compound, | ||
mixture, or preparation that contains any quantity of a natural or | ||
synthetic chemical substance, including its salts, isomers, and | ||
salts of isomers, listed by name in this subsection or contained | ||
within one of the structural classes defined in this subsection: | ||
(1) WIN-55,212-2; | ||
(2) Cyclohexylphenol: any compound structurally | ||
derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the | ||
5-position of the phenolic ring, (N-methylpiperidin-2-yl)alkyl, | ||
(4-tetrahydropyran)alkyl, or 2-(4-morpholinyl)alkyl, whether or | ||
not substituted in the cyclohexyl ring to any extent, including: | ||
JWH-337; | ||
JWH-344; | ||
CP-55,940; | ||
CP-47,497; and | ||
analogues of CP-47,497; | ||
(3) Cannabinol derivatives, except where contained in | ||
marihuana, including tetrahydro derivatives of cannabinol and | ||
3-alkyl homologues of cannabinol or of its tetrahydro derivatives, | ||
such as: | ||
Nabilone; | ||
HU-210; and | ||
HU-211; | ||
(4) Tetramethylcyclopropyl thiazole: any compound | ||
structurally derived from 2,2,3,3-tetramethyl-N-(thiazol- | ||
2-ylidene)cyclopropanecarboxamide by substitution at the nitrogen | ||
atom of the thiazole ring, whether or not further substituted in the | ||
thiazole ring to any extent, whether or not substituted in the | ||
tetramethylcyclopropyl ring to any extent, such as [ |
||
A-836,339; | ||
(5) any compound containing a core component | ||
substituted at the 1-position to any extent, and substituted at the | ||
3-position with a link component attached to a group A component, | ||
whether or not the core component or group A component are further | ||
substituted to any extent, such as [ |
||
Naphthoylindane; | ||
Naphthoylindazole (THJ-018); | ||
Naphthyl methyl indene (JWH-171); | ||
Naphthoylindole (JWH-018); | ||
Quinolinoyl pyrazole carboxylate (Quinolinyl | ||
fluoropentyl fluorophenyl pyrazole carboxylate); | ||
Naphthoyl pyrazolopyridine; and | ||
Naphthoylpyrrole (JWH-030); | ||
(6) any compound containing a core component | ||
substituted at the 1-position to any extent, and substituted at the | ||
2-position with a link component attached to a group A component, | ||
whether or not the core component or group A component are further | ||
substituted to any extent, such as [ |
||
Naphthoylbenzimidazole (JWH-018 Benzimidazole); | ||
and | ||
Naphthoylimidazole; | ||
(7) any compound containing a core component | ||
substituted at the 3-position to any extent, and substituted at the | ||
2-position with a link component attached to a group A component, | ||
whether or not the core component or group A component are further | ||
substituted to any extent, such as [ |
||
Naphthoyl benzothiazole; [ |
||
(8) any compound containing a core component | ||
substituted at the 9-position to any extent, and substituted at the | ||
3-position with a link component attached to a group A component, | ||
whether or not the core component or group A component are further | ||
substituted to any extent, including: | ||
Naphthoylcarbazole (EG-018); and | ||
Synthetic chemical compounds with a carbazole | ||
core structure, regardless of numerical designation of atomic | ||
positions, since this core structure is symmetrical; | ||
(9) any compound containing a core component | ||
substituted at the 1-position to any extent and substituted at the | ||
5-position with a link component attached to a group A component, | ||
regardless of whether the core component or group A component are | ||
further substituted to any extent, such as: | ||
5-fluoro-3,5-ADB-PFUPPYCA (5f-AB-PFUPPYCA); | ||
(10) any compound containing a core component | ||
substituted at the 2-position to any extent and substituted at the | ||
3-position with a link component attached to a group A component, | ||
regardless of whether the core component or group A component are | ||
further substituted to any extent, such as: | ||
AB-CHMINACA (2H) indazole; and | ||
(11) any compound containing a core component | ||
substituted at the 5-position to any extent and substituted at the | ||
2-position with a group A component, regardless of whether the core | ||
component or group A component are further substituted to any | ||
extent, such as: | ||
Cumyl-PeGACLONE. | ||
(c) In this section, a synthetic chemical substance | ||
analogue is: | ||
(1) any substance, unless specifically excepted, that | ||
has two of the three components as defined by Subsection (a) and a | ||
numerical core-link position that is listed in Subsection (b)(5), | ||
(6), (7), (8), (9), or (10); | ||
(2) any substance, unless specifically excepted, that | ||
has a core, link, and group A component as defined by Subsection (a) | ||
but does not have a numerical core-link position that is listed in | ||
Subsection (b)(5), (6), (7), (8), (9), or (10); or | ||
(3) any substance, unless specifically excepted, that | ||
has a core component or group A component as defined by Subsection | ||
(a) and a numerical core-group A position that is listed in | ||
Subsection (b)(11). | ||
SECTION 4. The change in law made by this Act applies only | ||
to an offense committed on or after the effective date of this Act. | ||
An offense committed before the effective date of this Act is | ||
governed by the law in effect on the date the offense was committed, | ||
and the former law is continued in effect for that purpose. For | ||
purposes of this section, an offense was committed before the | ||
effective date of this Act if any element of the offense occurred | ||
before that date. | ||
SECTION 5. This Act takes effect September 1, 2019. |